Nathan S. Kline Institute, Orangeburg, NY, USA 10962.
Nathan S. Kline Institute, Orangeburg, NY, USA 10962; Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA 10016.
Neurobiol Dis. 2018 Dec;120:165-173. doi: 10.1016/j.nbd.2018.08.025. Epub 2018 Sep 1.
Cystatin C (CysC) plays diverse protective roles under conditions of neuronal challenge. We investigated whether CysC protects from trisomy-induced pathologies in a mouse model of Down syndrome (DS), the most common cause of developmental cognitive and behavioral impairments in humans. We have previously shown that the segmental trisomy mouse model, Ts[Rb(12.1716)]2Cje (Ts2) has DS-like neuronal and behavioral deficiencies. The current study reveals that transgene-mediated low levels of human CysC overexpression has a preventive effect on numerous neuropathologies in the brains of Ts2 mice, including reducing early and late endosome enlargement in cortical neurons and decreasing loss of basal forebrain cholinergic neurons (BFCNs). Consistent with these cellular benefits, behavioral dysfunctions were also prevented, including deficits in nesting behavior and spatial memory. We determined that the CysC-induced neuroprotective mechanism involves activation of the phosphotidylinositol kinase (PI3K)/AKT pathway. Activating this pathway leads to enhanced clearance of accumulated endosomal substrates, protecting cells from DS-mediated dysfunctions in the endosomal system and, for BFCNs, from neurodegeneration. Our findings suggest that modulation of the PI3/AKT pathway offers novel therapeutic interventions for patients with DS.
半胱氨酸蛋白酶抑制剂 C(CysC)在神经元受到挑战的情况下发挥多种保护作用。我们研究了 CysC 是否能保护唐氏综合征(DS)小鼠模型免受三体诱导的病变,DS 是人类发育性认知和行为障碍的最常见原因。我们之前已经表明,片段性三体小鼠模型 Ts[Rb(12.1716)]2Cje(Ts2)具有与 DS 相似的神经元和行为缺陷。本研究揭示了转基因介导的低水平人 CysC 过表达对 Ts2 小鼠大脑中的许多神经病理学具有预防作用,包括减少皮质神经元中早期和晚期内体的扩大,并减少基底前脑胆碱能神经元(BFCN)的丢失。与这些细胞益处一致,行为功能障碍也得到了预防,包括筑巢行为和空间记忆缺陷。我们确定 CysC 诱导的神经保护机制涉及磷酸肌醇激酶(PI3K)/AKT 途径的激活。激活该途径可导致积累的内体底物的清除增强,从而保护细胞免受 DS 介导的内体系统功能障碍,以及 BFCN 免受神经退行性变的影响。我们的研究结果表明,PI3/AKT 途径的调节为 DS 患者提供了新的治疗干预措施。